Canada
· Delayed Price · Currency is CAD Rapid Dose Therapeutics Statistics
Total Valuation
CSE:DOSE has a market cap or net worth of CAD 24.40 million. The enterprise value is 26.97 million.
| Market Cap | 24.40M |
| Enterprise Value | 26.97M |
Important Dates
The last earnings date was Tuesday, January 28, 2025.
| Earnings Date | Jan 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CSE:DOSE has 128.44 million shares outstanding. The number of shares has increased by 16.59% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 128.44M |
| Shares Change (YoY) | +16.59% |
| Shares Change (QoQ) | +0.86% |
| Owned by Insiders (%) | 10.54% |
| Owned by Institutions (%) | n/a |
| Float | 114.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.24 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.67 |
| EV / Sales | 16.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.20
| Current Ratio | 0.20 |
| Quick Ratio | 0.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.32 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -135.70% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 266.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.88 |
| Inventory Turnover | 2.77 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.71% in the last 52 weeks. The beta is 0.71, so CSE:DOSE's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | +35.71% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.21 |
| Relative Strength Index (RSI) | 43.86 |
| Average Volume (20 Days) | 47,272 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CSE:DOSE had revenue of CAD 1.61 million and -5.78 million in losses. Loss per share was -0.05.
| Revenue | 1.61M |
| Gross Profit | 959,829 |
| Operating Income | -3.98M |
| Pretax Income | -5.78M |
| Net Income | -5.78M |
| EBITDA | -3.90M |
| EBIT | -3.98M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 40,099 in cash and 2.61 million in debt, giving a net cash position of -2.57 million or -0.02 per share.
| Cash & Cash Equivalents | 40,099 |
| Total Debt | 2.61M |
| Net Cash | -2.57M |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | -4.10M |
| Book Value Per Share | -0.03 |
| Working Capital | -2.52M |
Cash Flow
| Operating Cash Flow | -2.44M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 59.64% |
| Operating Margin | -247.18% |
| Pretax Margin | -358.96% |
| Profit Margin | n/a |
| EBITDA Margin | -242.62% |
| EBIT Margin | -247.18% |
| FCF Margin | n/a |
Dividends & Yields
CSE:DOSE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.59% |
| Shareholder Yield | -16.59% |
| Earnings Yield | -23.67% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CSE:DOSE has an Altman Z-Score of -42.32. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -42.32 |
| Piotroski F-Score | n/a |